Latest Oncology News

Adjuvant Metformin Does Not Improve Survival Outcomes in Early Breast Cancer

Adjuvant Metformin Does Not Improve Survival Outcomes in Early Breast Cancer

December 7th 2021

Ariana Pelosci

Metformin failed to improve invasive disease-free survival or overall survival when used as adjuvant treatment in patients with early breast cancer, irrespective of estrogen or progesterone receptor status.

Larkin Unpacks the Effect of Anti–PD-L1 Therapy on TIL Activity in Melanoma

Larkin Unpacks the Effect of Anti–PD-L1 Therapy on TIL Activity in Melanoma

December 7th 2021

Brittany Lovely

The role of adoptive cell therapy with tumor-infiltrating lymphocytes for patients with melanoma has undergone scrutiny as efforts to unpack the correlation between the duration of prior immunotherapy and efficacy outcomes.

Tamoxifen May Increase Risk of Secondary Uterine Cancer In Select Patients With Primary Breast Cancer

Tamoxifen May Increase Risk of Secondary Uterine Cancer In Select Patients With Primary Breast Cancer

December 7th 2021

Hayley Virgil

Patients with primary breast cancer who developed secondary uterine cancer following treatment with tamoxifen may have had disease driven by PI3K-pathway activation.

Breast Cancer–Related Lymphedema Occurs More Often in Black Women Vs White Women

Breast Cancer–Related Lymphedema Occurs More Often in Black Women Vs White Women

December 7th 2021

Ryan McDonald

The highest incidence of lymphedema observed was among the Black women with a 24-month lymphedema rate of 39.4%.

Fulvestrant/Palbociclib Following AI/Palbociclib Doubles PFS in HR+/HER2- Metastatic Breast Cancer

Fulvestrant/Palbociclib Following AI/Palbociclib Doubles PFS in HR+/HER2- Metastatic Breast Cancer

December 7th 2021

Jessica Hergert

Patients with hormone receptor–positive, HER2-negative metastatic breast cancer with rising ESR1 mutations previously treated with an aromatase inhibitor plus palbociclib had a doubling of progression-free survival when switched to fulvestrant plus palbociclib before disease progression, according to findings from the phase 3 PADA-1 trial.

Latest Oncology Videos

All Oncology News

Elacestrant Significantly Improves PFS in Advanced ER+ Breast Cancer, Including ESR1-Mutant Subtype

December 7th 2021

Gina Mauro

The selective estrogen receptor degrader elacestrant (RAD1901) led to a 30% reduction in the risk of disease progression or death compared with standard of care in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who previously received CDK4/6 inhibition.

Matched Targeted Therapy Improves PFS Through Multigene Sequencing in Metastatic Breast Cancer

December 7th 2021

Caroline Seymour

Genomic alterations identified through multigene sequencing, classified in the I/II tiers of the ESMO Scale of Actionability of Molecular Targets, and paired with matching targeted therapy led to a significant improvement in progression-free survival vs maintenance chemotherapy in patients with HER2-negative metastatic breast cancer.

Single-Cell Spatial Analysis for Immunotherapy Response Prediction in Early TNBC Shows Promise

December 7th 2021

Audrey Sternberg

Imaging mass cytometry at the single-cell level showed potential as an immunotherapy response prediction tool in early triple-negative breast cancer.

FDA Grants 510K Clearance to Exablate System for Prostate Cancer

December 6th 2021

Jason Harris

The FDA has awarded 510K clearance to the Exablate Prostate system for the treatment of prostate cancer.

FDA Grants Fast Track Designation to ST101 for Recurrent Glioblastoma

December 6th 2021

Courtney Marabella

The FDA has granted a fast track designation to ST101, a peptide antagonist of C/EBPβ, for the treatment of patients with recurrent glioblastoma.

FDA Approval Insights: Adjuvant Pembrolizumab in RCC

December 6th 2021

OncLive Staff

Dr. Choueiri discusses the significance of the FDA approval of pembrolizumab as adjuvant therapy in renal cell carcinoma and key data from the pivotal phase 3 KEYNOTE-564 trial.

FDA Approval Sought for Poziotinib in HER2 Exon 20–Mutated NSCLC

December 6th 2021

Kristi Rosa

A new drug application seeking the approval of poziotinib as a potential therapeutic option for patients with previously treated locally advanced or metastatic non–small cell lung cancer with HER2 exon 20 insertion mutations has been submitted to the FDA.

MRD-Guided Treatment Represents the Future in CLL

December 6th 2021

Maggie Tibbitt

William G. Wierda, MD, PhD, discussed the results of the phase 2 CAPTIVATE trial and the phase 1/2 TRANSCEND CLL 004 trial, and looked ahead to what the future holds for MRD in patients with CLL.

Secura Bio Withdraws Duvelisib Relapsed/Refractory Follicular Lymphoma Indication in the United States

December 6th 2021

Kristi Rosa

Secura Bio, Inc. has decided to voluntarily withdraw the indication of duvelisib for use in patients with relapsed or refractory follicular lymphoma following at least 2 previous systemic therapies.

Breast Reconstruction Specialist Dr. Andrea Moreira Joins AHN from Cleveland Clinic

December 6th 2021

Andrea Moreira, MD, a board-certified plastic surgeon specializing in the use of advanced techniques in breast reconstruction, has joined Allegheny Health Network from Cleveland Clinic and will serve as Co-Director of the Microsurgery and Breast Reconstruction Program in the AHN Division of Plastic Surgery.

Therapeutic Frontiers Expand for Patients With Relapsed/Refractory Multiple Myeloma

December 6th 2021

Shambavi Richard, MD

Various immune strategies have been developed in multiple myeloma, including immune-enhancing drugs such as immunomodulatory drugs, checkpoint inhibitors, monoclonal antibodies, and, more recently, chimeric antigen receptor T-cell therapy and bispecific antibodies for T-cell redirection.

Pirtobrutinib Provides Promising Results in Richter Transformation

December 6th 2021

Ryan Scott

Meghan Thompson, MD, discusses the results from the use of pirtobrutinib in the phase 1/2 BRUIN study, as well as upcoming research efforts in the population of patients with Richter transformation.

Ripretinib Demonstrates Impressive Efficacy, Durability in Heavily Pretreated KIT-Mutated Melanoma

December 6th 2021

Maggie Tibbitt

Filip Janku, MD, PhD, discusses the phase 1 study with ripretinib in patients with KIT-mutated or KIT-amplified melanoma.

Ribociclib/Everolimus Elicits Responses in Dedifferentiated Liposarcoma

December 5th 2021

Maggie Tibbitt

Margaret von Mehren, MD, discusses the value of ribociclib plus everolimus for patients with dedifferentiated liposarcoma, and how further research will be focused on biomarker analysis.

Image-Guided Intensity-Modulated Radiotherapy Shows Reduced Toxicity in Cervical Cancer

December 4th 2021

Caroline Seymour

Image-guided intensity-modulated radiotherapy caused less toxicity compared with three-dimensional conformal radiation therapy with no difference in disease outcomes in patients with cervical cancer undergoing postoperative radiation therapy.

See All News